EVOLVE Short DAPT with the SYNERGY BP Stent - YouTube
Studying DAPT – SYNERGY Stent - Boston Scientific
EVOLVE Short DAPT: A Single-Arm Study of 3-Month DAPT in Patients at High Bleeding Risk Treated With a Bioabsorbable Polymer-Based Everolimus-Eluting Stent | tctmd.com
Primary Results of the EVOLVE Short DAPT Study | Circulation: Cardiovascular Interventions
EVOLVE Short DAPT Trial – SYNERGY Stent - Boston Scientific
SYNERGY™ Clinical Program - Short DAPT - Boston Scientific
Another Coronary Stent for Patients at High Bleeding Risk∗ | JACC: Cardiovascular Interventions
EVOLVE SHORT-DAPT: Three-Month Outcomes on Dual Antiplatelet Therapy in a High Bleeding Risk Population Treated With a Bioresorbable Polymer-Based Drug-Eluting Stent | tctmd.com
PDF) Evolving Concepts in Post-PCI Antiplatelets Therapy
XIENCE Stent: Protecting Patients with Short DAPT Needs | Abbott
Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT | tctmd.com
Evolving Concepts in Post-PCI Antiplatelets Therapy - Kartik Pandurang Jadhav, Pankaj V. Jariwala, 2020
Session evaluation and key learnings
Complex Coronary Cases - ppt download
EVOLVE Short DAPT Trial – SYNERGY Stent - Boston Scientific
EVOLVE Short DAPT Trial Enrollment Complete - Boston Scientific
Evolution of Coronary Stent Technology and Implications for Duration of Dual Antiplatelet Therapy - ScienceDirect
EVOLVE Short DAPT in Print: P2Y12 Decisions Can Safely Be Made Case-by-Case | tctmd.com
SYNERGY™ Clinical Program - Short DAPT - Boston Scientific
Synergy: Short DAPT Study - ppt download
3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation | JACC: Cardiovascular Interventions
